EGFR and non-small cell lung carcinoma: First-generation (gefitinib, erlotinib) and second-generation (afatinib, dacomitinib) EGFR-tyrosine kinase inhibitors (TKIs) with platinum-based doublet chemotherapy established first- and second-generation EGFR-TKIs as the standard-of-care for patients with EGFR-mutated advanced NSCLC.